Christopher Haqq

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Brisbane, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Christopher Haqq
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Christopher Haqq

Form 4 holding Former Director

Surrozen, Inc./DE

Security class
Common Stock
Shares / value
30,000
Estimated value
$11,400
Report date
11 Aug 2021
Price
$0.3800
Ownership
Direct
Form 4 holding Executive Vice President, Head of R&D and Chief Medical Officer

Elicio Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
64,643
Estimated value
Report date
16 Jul 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Former Director

Surrozen, Inc./DE

Security class
Class B Ordinary Shares
Shares / value
0
Estimated value
Report date
11 Aug 2021
Price
Ownership
Direct
Underlying class
Class A Ordinary Shares
Underlying amount

Insider Reports Filed by Christopher Haqq

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .